Form 4: Avalo Therapeutics Insider Trades Common Stock

Avalo Therapeutics, Inc. reports insider transactions involving the acquisition and disposition of common stock and stock options by Chief Medical Officer Mittie Doyle.

Summary

• Mittie Doyle, Chief Medical Officer of Avalo Therapeutics, Inc., engaged in transactions involving common stock and stock options on April 6, 2026.
• Doyle acquired 3,970 shares of common stock at a price of $12.65 per share.
• Concurrently, Doyle disposed of 3,970 shares of common stock at prices ranging from $18.00 to $18.10.
• These transactions were executed under a Rule 10b5-1 trading plan adopted on November 13, 2025.
• Following these transactions, Doyle beneficially owns 3,622 shares of common stock directly and 210,530 shares through stock options.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral. While the transactions were executed under a pre-planned Rule 10b5-1, the sale of shares by a key executive can be interpreted in various ways by the market.

Positives

• The transactions were conducted under a pre-established Rule 10b5-1 trading plan, indicating a structured and pre-determined approach to trading.
• The acquisition of shares at a lower price ($12.65) and disposition at a higher price ($18.00-$18.10) suggests a profitable execution of the plan.
• The reporting person continues to hold a significant number of shares and stock options, indicating continued commitment to the company.

Negatives

• The disposition of a substantial number of shares (3,970) by a key executive could be perceived negatively by the market, despite being part of a plan.
• The sale of shares at prices significantly higher than the acquisition price, while profitable for the individual, represents a transfer of value out of the company's stock.

Risks

• The Rule 10b5-1 plan is subject to market conditions and the company's performance, which could impact future transactions.
• The disposition of shares by an executive might signal a lack of confidence in short-term stock appreciation, although this is mitigated by the plan's nature.

Future Outlook

The filing does not contain forward-looking statements or guidance. The transactions are based on a pre-existing trading plan.

Management Comments

• The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
• The reported securities were sold in multiple transactions at prices ranging from $18.00 to $18.10. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within such range.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those under Rule 10b5-1 plans, are common in the biotechnology sector as executives manage personal portfolios while adhering to regulatory requirements. The execution of such plans can provide liquidity for executives while aiming to avoid perceptions of insider trading.

Stakeholder Impact

• Shareholders: May interpret the sale of shares by an executive as a signal, though the Rule 10b5-1 plan mitigates this concern to some extent.
• Employees: May observe executive trading patterns as an indicator of company health or executive confidence.
• Management: The transactions reflect the executive's personal financial planning and adherence to regulatory frameworks.

Next Steps

• The reporting person may continue to execute transactions under the Rule 10b5-1 plan as per its terms.
• The company may receive requests for further information regarding the specific prices of the disposed securities.

Key Dates

Keywords

Avalo Therapeutics, AVTX, Form 4, Insider Trading, Stock Options, Common Stock, Rule 10b5-1, Beneficial Ownership, Executive Transactions, Securities Exchange Act